Compare NIO Inc. (NIO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Novo Nordisk A/S — how do they compare? NIO Inc. trades at $3.65 (market cap $9.23B), while Novo Nordisk A/S trades at $44.71 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 21.7× NIO Inc.'s market cap, and Novo Nordisk A/S pays a 3.98% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | NVO | |
|---|---|---|
Market Cap | $9.23B | $200.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $63.98 |
52-Week Low | $3.70 | $35.29 |
Enterprise Value | $7.13B | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.79, down 0.26% over 24 hours, with a bearish technical signal but improving fundamentals. Recent Q2 2026 earnings beat expectations with a narrower loss, while revenue grew 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03). The stock faces headwinds from a weak Chinese EV market but shows progress toward profitability with positive operating cash flow in Q2.
The outlook is mixed: analyst consensus is bullish with a $5.50 price target (50% buy ratings), but risks include high debt, competition, and macroeconomic pressures. Upside depends on sustained delivery growth and margin expansion, while downside risks loom from cost inflation and market sentiment shifts.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
